DeepMed Research

Sinovac Research And Development Co Ltd

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Phase 3

Completed

Conditions: Mumps

Interventions: Biological: Investigational live attenuated mumps vaccine
Biological: control live attenuated mumps vaccine

First Posted Date: 2021-10-01

Last Posted Date: 2021-10-01

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 1140

Registration Number: NCT05065177

Locations: 🇨🇳
Dingxing County Center for Disease Control and Prevention, Dingxing, Hebei, China

Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

Phase 4

Completed

Conditions: COVID-19

Interventions: Biological: Experimental Group
Biological: Control Group

First Posted Date: 2021-08-06

Last Posted Date: 2023-10-10

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 520

Registration Number: NCT04993365

Locations: 🇨🇳
Zhanjiang Center for Disease Control and Prevention, Zhanjiang, Guangdong, China
🇨🇳
Yangchun Center for Disease Control and Prevention, Yangchun, Guangdong, China

Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: Controlled vaccine
Biological: Inactivated COVID-19 Vaccine

First Posted Date: 2021-08-05

Last Posted Date: 2023-10-16

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 11349

Registration Number: NCT04992260

Locations: 🇵🇭
Philippine Children's Medical Center, Manila, Philippines
🇵🇭
Philippine General Hospital, Manila, Philippines
🇵🇭
Asian Hospital and Medical Center, Muntinlupa, Philippines

and more 34 locations

Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic

Completed

Conditions: COVID-19

Interventions: Biological: Inactivated COVID-19 Vaccine

First Posted Date: 2021-07-23

Last Posted Date: 2022-08-23

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 1400

Registration Number: NCT04974164

Locations: 🇩🇴
Centro Médico Bournigal, San Felipe de Puerto Plata, Puerto Plata, Dominican Republic
🇩🇴
Felix Maria Goico Hospital, Villa Francisca, Distrito Nacional, Dominican Republic
🇩🇴
JoséM.Cabral V Báez, Puñal, Santiago, Dominican Republic

and more 7 locations

Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

Phase 4

Conditions: COVID-19

Interventions: Biological: The SARS-CoV-2 Inactivated Vaccine
Biological: SARS-CoV-2 Inactivated Vaccine

First Posted Date: 2021-07-14

Last Posted Date: 2021-09-24

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 1400

Registration Number: NCT04962308

Locations: 🇨🇳
Beijing Centers for Diseases Control and Prevention, Beijing, China

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine

Phase 4

Completed

Conditions: COVID-19

Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine
Biological: Inactivated COVID-19 Vaccine
Biological: Inactivated Hepatitis A Vaccine

First Posted Date: 2021-07-07

Last Posted Date: 2022-04-14

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 270

Registration Number: NCT04953325

Locations: 🇨🇳
Rushan City Center for Disease Control and Prevention, Weihai, Shandong, China

Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults

Phase 4

Completed

Conditions: COVID-19

Interventions: Biological: Experimental Group

First Posted Date: 2021-06-03

Last Posted Date: 2023-09-25

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 131650

Registration Number: NCT04911790

Locations: 🇨🇳
Yongping Center for Diseases Control and Prevention, Dali, Yunnan, China

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

Phase 4

Completed

Conditions: COVID-19

Interventions: Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell）

First Posted Date: 2021-05-20

Last Posted Date: 2022-04-13

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 1080

Registration Number: NCT04894227

Locations: 🇨🇳
Jingliang Wu, Huai'an, Jiangsu, China

Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine

Phase 4

Completed

Conditions: COVID-19
Influenza

Interventions: Biological: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.
Biological: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.

First Posted Date: 2021-03-17

Last Posted Date: 2021-07-26

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 480

Registration Number: NCT04801888

Locations: 🇨🇳
Kaihua county Center for Disease Control and Prevention, Quzhou, Zhejiang, China

Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults

Phase 3

Completed

Conditions: Covid19

Interventions: Biological: Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14
Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly
Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14

First Posted Date: 2020-11-05

Last Posted Date: 2021-07-27

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 1040

Registration Number: NCT04617483

Locations: 🇨🇳
Dafeng District Center for Disease Prevention and Control, Yancheng, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy